Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants

17 november 2026 uppdaterad av: Beijing Suncadia Pharmaceuticals Co., Ltd

A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants

This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.

Studieöversikt

Status

Rekrytering

Betingelser

Studietyp

Interventionell

Inskrivning (Beräknad)

50

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Anhui
      • Hefei, Anhui, Kina, 230000
        • Rekrytering
        • The First Affiliated Hospital of University of Science and Technology of China
        • Huvudutredare:
          • Jiong Shi
        • Huvudutredare:
          • Zhaoyi Yang
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 60 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
  2. Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
  3. Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
  4. Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.

Exclusion Criteria:

  1. Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
  2. Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
  3. Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
  4. Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
  5. Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
  6. Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
  7. Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
  8. Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
  9. Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
  10. Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
  11. Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
  12. Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
  13. Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
  14. Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
  15. Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
  16. Are pregnant or lactating females;
  17. Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
  18. Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dose 1 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 1.

SHR 3201 injection.

SHR 3201 placebo.

Experimentell: Dose 2 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 2.

SHR 3201 injection.

SHR 3201 placebo.

Experimentell: Dose 3 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 3.

SHR 3201 injection.

SHR 3201 placebo.

Experimentell: Dose 4 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 4.

SHR 3201 injection.

SHR 3201 placebo.

Experimentell: Dose 5 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 5.

SHR 3201 injection.

SHR 3201 placebo.

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Adverse events (AEs)
Tidsram: From pre-dose to 36 days post-dose.
From pre-dose to 36 days post-dose.

Sekundära resultatmått

Resultatmått
Tidsram
Serum concentration of SHR-3201 after single-dose administration
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Time to peak concentration (Tmax)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Peak concentration (Cmax)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Elimination half-life (T1/2)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Clearance (CL)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Steady-state volume of distribution (Vss)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Bioavailability of SHR-3201 following subcutaneous administration
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Incidence of anti-drug antibodies (ADA)
Tidsram: From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 november 2026

Primärt slutförande (Beräknad)

1 januari 2027

Avslutad studie (Beräknad)

1 februari 2027

Studieregistreringsdatum

Först inskickad

16 oktober 2026

Först inskickad som uppfyllde QC-kriterierna

16 oktober 2026

Första postat (Faktisk)

22 oktober 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera